How to Read a Peptide Study
Species, endpoints, controls, and effect sizes — the four checks that separate real findings from marketing citations.
Check the species first
Most peptide "evidence" is rodent work. A rat Achilles transection model can show real biology and still tell you nothing about a human tendon under progressive rehab. Any claim that skips from mouse to man without a human trial in between is extrapolation, not evidence.
Endpoints and controls
- An endpoint is what the study actually measured — fibroblast outgrowth is not the same as return-to-sport time.
- Uncontrolled case series cannot separate compound effects from natural healing; look for placebo or comparator arms.
- Route matters: oral gut-model data cannot support injectable tendon claims, and vice versa.
Effect sizes and failed programs
Statistically significant is not clinically meaningful — MK-677 added about 1.1 kg of fat-free mass over a full year, and AOD-9604 was safe yet failed efficacy in obesity trials. A discontinued development program is itself a data point: someone with money reviewed the numbers and stopped paying.
Knowledge check
Answer 5 questions — 4 correct passes and earns 50 points.
1. A study shows BPC-157 improves healing in transected rat tendons. What does this establish for humans?
2. Which is a clinical endpoint rather than a surrogate?
3. Why do uncontrolled case reports mislead for healing compounds?
4. MK-677 raised fat-free mass ~1.1 kg over 12 months without strength gains. The honest read is:
5. A pharma company halts development after phase II misses endpoints. That fact is:
Points are credited once per module, up to 5 point-earning completions per calendar month. Back to all modules